---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Real-world evidence questions"
description: "Real-world evidence questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Is an early Trelegy start after a first COPD exacerbation linked to fewer exacerbations? Is an early Trelegy start linked to a later next COPD exacerbation? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/real-world-evidence"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Real-world evidence questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)

Questions that apply to every indication of Trelegy Ellipta are on [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications](https://www.evicenter.com/medical-information/trelegy-ellipta).

## Real-world evidence

<a id="trelegy-early-start-exacerbations"></a>

### Is an early Trelegy start after a first COPD exacerbation linked to fewer exacerbations?

> “Study description: A retrospective cohort study used IQVIA data in primarily commercially insured patients to evaluate early (0-30 days) vs delayed (31-180 days) TRELEGY initiation after their first moderate or severe COPD exacerbation. A total of 5421 patients ≥40 years of age (mean age: 62 years) were included. At first exacerbation, 76% of patients had a moderate exacerbation and 24% had a severe (hospitalized) exacerbation. Select inhaled maintenance treatments used any time during the 12-month baseline period included ICS/LABA (34%), LAMA (14%), and LAMA/LABA (14%). This study did not exclude patients with an asthma diagnosis code. However, patients with asthma were not included in TRELEGY COPD clinical trials.”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=Study%20description%3A%20A%20retrospective%20cohort,in%20TRELEGY%20COPD%20clinical%20trials.)

On the page, select: Real-world study description and considerations1

> “Results are descriptive only.”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=Results%20are%20descriptive%20only.)

On the page, select: Real-world study description and considerations1

> “Delayed TRELEGY initiation is associated with a
>
> 2.17
>
> %
>
> GREATER RISK OF EXACERBATION PER WEEK<sup>1†</sup>”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=Delayed%20TRELEGY%20initiation%20is%20associated,GREATER%20RISK%20OF%20EXACERBATION%20PER)

On the page, select: Real-world study description and considerations1

> “ONE-DAY RATE INCREASE VS EARLY INITIATION (95% CI): 0.31% (0.23%, 0.38%)”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=ONE%2DDAY%20RATE%20INCREASE%20VS%20EARLY%20INITIATION%20%2895%25%20CI%29%3A%200.31%25%20%280.23%25%2C%200.38%25%29)

On the page, select: Real-world study description and considerations1

> “<sup>†</sup>Based on a one-day change in exacerbation rate using the coefficient on time to FF/UMEC/VI from a Poisson regression model.”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=on%20a%20one%2Dday%20change%20in,from%20a%20Poisson%20regression%20model.)

On the page, select: Real-world study description and considerations1

> “Important study considerations:
>
> Real-world studies are designed to evaluate associations among variables and not to definitively establish causality.
> Differences exist in patient populations and data collection vs randomized controlled trials.
> Findings may not be generalizable to uninsured or other insured US populations.
> A claim for a filled prescription does not indicate that the medication was taken as prescribed.”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=Important%20study%20considerations%3A,medication%20was%20taken%20as%20prescribed.)

On the page, select: Real-world study description and considerations1

Note: Early initiation was 0 to 30 days and delayed initiation 31 to 180 days after the first exacerbation.

<a id="trelegy-early-start-next-exacerbation"></a>

### Is an early Trelegy start linked to a later next COPD exacerbation?

> “Study description: A retrospective cohort study used IQVIA data in primarily commercially insured patients to evaluate early (0-30 days) vs delayed (31-180 days) TRELEGY initiation after their first moderate or severe COPD exacerbation. A total of 5421 patients ≥40 years of age (mean age: 62 years) were included. At first exacerbation, 76% of patients had a moderate exacerbation and 24% had a severe (hospitalized) exacerbation. Select inhaled maintenance treatments used any time during the 12-month baseline period included ICS/LABA (34%), LAMA (14%), and LAMA/LABA (14%). This study did not exclude patients with an asthma diagnosis code. However, patients with asthma were not included in TRELEGY COPD clinical trials.”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=Study%20description%3A%20A%20retrospective%20cohort,in%20TRELEGY%20COPD%20clinical%20trials.)

On the page, select: Real-world study description and considerations1

> “Results are descriptive only.”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=Results%20are%20descriptive%20only.,-At%2012%20months)

On the page, select: Real-world study description and considerations1

> “At 12 months after first exacerbation, 43.2% of patients with early TRELEGY initiation (n=2057) vs 55.9% with delayed TRELEGY initiation (n=3364) had an additional exacerbation, HR: (95% CI): 0.68 (0.62, 0.73).<sup>1</sup>”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=At%2012%20months%20after%20first,HR%3A%20%2895%25%20CI%29%3A%200.68%20%280.62%2C)

On the page, select: Real-world study description and considerations1

> “Important study considerations:
>
> Real-world studies are designed to evaluate associations among variables and not to definitively establish causality.
> Differences exist in patient populations and data collection vs randomized controlled trials.
> Findings may not be generalizable to uninsured or other insured US populations.
> A claim for a filled prescription does not indicate that the medication was taken as prescribed.”

Source: [TRELEGY ELLIPTA: Early vs Delayed Initiation Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/early-initiation-results/#:~:text=Important%20study%20considerations%3A,medication%20was%20taken%20as%20prescribed.)

On the page, select: Real-world study description and considerations1

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/guidelines)
